Name: SKY-0515 in Huntington's disease: Cost assumptions
Published: 2026-09-16T18:00:43-04:00

Economic information and modeling report Budget impact model

Cost assumptions

2 evidence topics · 3 sources

Launch prices of oral drugs for rare neurological diseases: Skyclarys and Daybue

“Reata announced that Skyclarys would have a wholesale acquisition price of $370,000 annually.” (opens the source at this quote in a new tab)

“The list price of Daybue will be $21.10 per milliliter, or an estimated average net realized cost to payors of about $375,000 annually” (opens the source at this quote in a new tab)

SKY-0515: safety and efficacy assessments named in the phase 2/3 study record

“Safety and efficacy will be evaluated through blood tests, imaging (MRI), and clinical assessments, including the Unified Huntington's Disease Rating Scale (UHDRS).” (opens the source at this quote in a new tab)